Related Experiment Video
Updated: Apr 5, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
22.8K
Obinutuzumab in chronic lymphocytic leukemia
1Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France.
Future Oncology (London, England)
|August 20, 2015
Summary
Obinutuzumab, a novel anti-CD20 antibody, shows improved outcomes when combined with chlorambucil for chronic lymphocytic leukemia. This combination is now a recommended first-line therapy for eligible patients.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Chronic lymphocytic leukemia (CLL) is a common B-cell malignancy.
- Next-generation monoclonal antibodies targeting CD20 are advancing CLL treatment.
- Obinutuzumab represents a significant development in anti-CD20 therapy.
Purpose of the Study:
- To evaluate the efficacy of obinutuzumab in combination with chlorambucil for first-line treatment of CLL.
- To establish obinutuzumab as a viable treatment option for patients unsuitable for intensive therapies.
Main Methods:
- Clinical trial comparing obinutuzumab plus chlorambucil versus chlorambucil alone.
- Focus on patient populations not candidates for intensive treatment regimens.
Main Results:
- Obinutuzumab in combination with chlorambucil demonstrated superiority over chlorambucil monotherapy.
- This led to the approval of obinutuzumab as a first-line treatment option.
Conclusions:
- Obinutuzumab plus chlorambucil is an effective first-line treatment for CLL.
- It offers a valuable therapeutic option for elderly or frail patients.
Keywords:
anti-CD20chronic lymphocytic leukemiainfusion-related reactionsminimal residual diseaseobinutuzumabMore Related Videos
Related Concept Videos
02:56Treatment Resistent Cancers
1.5K
1.5K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
02:57Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
01:16Primary Lymphoid Organs
16.8K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.8K